Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

June 14, 2019June 14, 2019

IBD Mortality Rates Down in Recent Years, but Still Higher Than General Population, Study Reports

News

Although mortality rates associated with inflammatory bowel disease (IBD) have declined substantially over recent years, patients diagnosed with IBD as adults still have a higher risk of death than the ... Read more

April 26, 2019April 26, 2019

New National Surveys on Medicinal Cannabis Use for IBD Symptoms Launched in Australia

News

Two new national surveys on the use of cannabis for the treatment of patients with inflammatory bowel disease (IBD) have been launched in Australia. The anonymous surveys — one designed ... Read more

April 5, 2019April 5, 2019

EMA Advances Under-the-skin Injection of Entyvio for Crohn’s and Ulcerative Colitis

News

The European Medicines Agency (EMA) has accepted a Marketing Authorization Line Extension Application for a new subcutaneous (under-the-skin) form of Entyvio (vedolizumab). Entyvio is a biologic agent developed by Millenium ... Read more

April 3, 2019April 3, 2019

UK’s NICE Publishes Briefing Supporting PredictImmune Tool for Estimating IBD Flare-up Likelihood

News

The National Institute for Health and Care Excellence (NICE) supports the use of PredictImmune‘s newly launched prognostic tool, PredictSURE IBD, for estimating the likelihoood of disease flare-ups in patients with ... Read more

March 27, 2019March 27, 2019

Underweight IBD Patients are More Susceptible to Fatty Liver Disease, Study Suggests

News

Underweight patients with inflammatory bowel disease may be more susceptible to developing non-alcoholic fatty liver disease than those with normal weight, according to a study. The study, “Non-alcoholic fatty liver ... Read more

March 18, 2019March 18, 2019

Program to Examine Gut Microbiota’s Role in Predicting Response to Therapies

News

uBiome launched a research collaboration program with clinicians from the University of Louisville in Kentucky to investigate the usefulness of the gut microbiome to predict the clinical response of patients ... Read more

February 18, 2019February 18, 2019

Humira Reduces Early Ulcerative Colitis Features, Trial Analysis Shows

News

AbbVie‘s Humira (adalimumab) reduces early tissue inflammation, rectal bleeding, and stool frequency in patients with ulcerative colitis, according to a post-hoc analysis of two Phase 3 trials. Findings were published in ... Read more

February 6, 2019February 6, 2019

Remote Monitoring Offers Little Benefit to IBD Patients, Study Finds

News

Telemedicine monitoring failed to increase inflammatory bowel disease patients’ confidence or motivation to manage their status, compared to standard routine care, a study reported. The study, “Effect of TELEmedicine for Inflammatory Bowel ... Read more

January 30, 2019January 30, 2019

Diet and Clear-Mindedness Most Affected Psychosocial Needs in IBD Patients, Study Reports

News

Among 10 different psychosocial needs, diet and a lack of clear-mindedness were the ones most patients with inflammatory bowel disease felt were affected by their disease, a study reports. The study, ... Read more

December 5, 2018December 5, 2018

Potential IBD Therapy PTG-200 Safe, Well-tolerated in Healthy Volunteers, Phase 1 Results Show

News

PTG-200, being developed by Protagonist Therapeutics in collaboration with Janssen Biotech for the treatment of moderate and severe Crohn’s disease, was found safe and well-tolerated in healthy volunteers, according to top-line results of ... Read more